Actively Recruiting ALS Clinical Trials

• antisense oligonucleotide treatment for people carrying a mutation in FUS gene
• recruiting in CA, MD, MA, MO, NY, OH, UT

• 33% chance of placebo
• trial volunteers will be separated into 3 groups, a high dose with riluzole, a low dose with riluzole, or placebo with riluzole
• recruiting in AL, CA, IL, KY, MD, MA, NY, PA

• 33% chance of placebo for 6 months followed by open label extension
• recruiting in AZ, CA, CO, DC, FL, IL, IN, IA, KS, MD, MA, MI, MO, NE, NY, NC, OH, OR, PA, TN, TX, VT, WI

• biomarkers will be monitored over time and tofersen or placebo will be administered if specific biomarker changes occur
• antisense oligonucleotide treatment for people carrying specific SOD1 mutations, but no current symptoms of ALS
• recruiting in AZ, CA, FL, GA, IL, MD, MA, MO, NY, TX

CLS-ABBV-7262

Regimen F

Healey Platform Trial

• 25% of placebo for 6 months followed by active treatment for all participants through open label extension
• 2 doses are being tested
• recruiting in CO, CT, FL, GA, MA, MI, MN, NE, TX, 

• 50% chance of placebo for 12 months followed by an open label extension for 6 months
• recruiting in CA, FL, GA, IN, KS, MD, MN, NY, NC, OR, PA, VA, WA

• no placebo
• drug is delivered intravenously for 22 weeks with additional 14 weeks of followup
• recruiting in AZ, CA, FL, NY

• placebo-controlled trial
• drug is delivered intravenously
• trial is for people carrying SOD1 mutation or sporadic ALS
• recruiting in CA

• no placebo
• multiple groups or “cohorts” with cohorts 1-4 all receiving treatment and PET imaging, while in cohort 5 participants will be split into two groups that will either receive PET imaging or contribute to spinal fluid analysis
• recruiting in CT, MA, NY

Dazucorilant

• no placebo
• allows participation up to 4 years from symptom onset
• recruiting in AZ, CO, FL, IL, KY, MO, NY

• no placebo
• trial is for people that carry a mutation in the C9orf72 gene
• recruiting in FL

• 50% chance of placebo for 24 weeks followed by 24 weeks of open label extension
• recruiting in CA, FL, KS, TX

• 33% chance of placebo for 24 weeks followed by 82 weeks of open label treatment
• recruiting in CA, CO, FL, MA, NY, PA, UT, WI

• no placebo
• recruiting in TX

• crossover study: all trial volunteers will receive placebo and all trial volunteers will receive active treatment at different timepoints
• recruiting in FL

• no placebo
• autologous T cells are administered intravenously for 6 months followed by an additional 6 months of observation
• recruiting in MA, NJ

• no placebo
• includes people living with different neurodegenerative diseases including ALS
• recruiting in MA

• placebo controlled trial
• antisense oligonucleotide treatment for people with sporadic ALS as well as people who carry the ataxin-2 gene mutation
• recruiting in CA, FL, GA, MD, MA, MO, PA, UT

• no placebo
• cells that produce GDNF (a growth factor) will be transplanted into motor cortex of brain
• recruiting in CA

• 50% chance of placebo
• trial duration is 9 months
• recruiting in NY